Current state of art for transplantation paradigms in peripheral T-cell lymphomas

References

• Petrich AM, Helenowski I, Galamaga RW, Nabhan C. Trends in incidence and outcome in T-cell lymphoma since 1992: a SEER database analysis. Blood 120(121), 1 (2012).
   PubMedGoogle Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26(25), 4124–4130 (2008).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92(1), 76–82 (1998).
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Zinzani Pl et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93(8), 2697–2706 (1999).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann. Oncol. 1(1), 45–50 (1990).
   PubMed Web of Science ®Google Scholar
• Mounier N, Simon D, Haioun C, Gaulard P, Gisselbrecht C. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J. Clin. Oncol. 20(5), 1426–1427 (2002).
   PubMed Web of Science ®Google Scholar
• Simon A, Peoch M, Casassus P et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized Phase III trial GOELAMS-LTP95. Br. J. Haematol. 151(2), 159–166 (2010).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7), 2316–2323 (2007).
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103(8), 2920–2924 (2004).
   PubMed Web of Science ®Google Scholar
• Kim Jg, Sohn Sk, Chae Ys et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a Phase II study. Cancer Chemother. Pharmacol. 60(1), 129–134 (2007).
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18), 3418–3425 (2010).
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333(23), 1540–1545 (1995).
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J. Clin. Oncol. 18(16), 3025–3030 (2000).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 20(10), 2472–2479 (2002).
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C, Briere J et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann. Oncol. 15(12), 1790–1797 (2004).
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Zallio F et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9), 1533–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur. J. Haematol. 79(1), 32–38 (2007).
   PubMed Web of Science ®Google Scholar
• Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann. Oncol. 19(5), 958–963 (2008).
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27(1), 106–113 (2009).
   PubMed Web of Science ®Google Scholar
• D'amore F, Relander T, Lauritzsen Gf et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J. Clin. Oncol. 30(25), 3093–3099 (2012).
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A et al. The adjusted international prognostic index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92(8), 1067–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Yang Dh, Kim Ws, Kim Sj et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol. Blood Marrow Transplant. 15(1), 118–125 (2009).
   PubMed Web of Science ®Google Scholar
• Numata A, Miyamoto T, Ohno Y et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 45(2), 311–316 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Ai, Mcmillan A, Negrin Rs, Horning Sj, Laport Gg. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol. Blood Marrow Transplant. 14(7), 741–747 (2008).
   PubMed Web of Science ®Google Scholar
• Feyler S, Prince Hm, Pearce R et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 40(5), 443–450 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann. Oncol. 18(4), 652–657 (2007).
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7), 2474–2479 (2004).
   PubMed Web of Science ®Google Scholar
• Song Kw, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br. J. Haematol. 120(6), 978–985 (2003).
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz Ad, Teruya-Feldstein J et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br. J. Haematol. 134(2), 202–207 (2006).
   PubMed Web of Science ®Google Scholar
• Blystad Ak, Enblad G, Kvaloy S et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 27(7), 711–716 (2001).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Wiklund T, Juvonen E et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 33(4), 405–410 (2004).
   PubMed Web of Science ®Google Scholar
• Federico M, Rudiger T, Bellei M et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J. Clin. Oncol. 31(2), 240–246 (2013).
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Goldstone A et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome – Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 26(2), 218–224 (2008).
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Angamuthu N, Boyd K et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 115(18), 3664–3670 (2010).
   PubMed Web of Science ®Google Scholar
• Dhedin N, Giraudier S, Gaulard P et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br. J. Haematol. 107(1), 154–161 (1999).
   PubMed Web of Science ®Google Scholar
• Kim Sw, Tanimoto Te, Hirabayashi N et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108(1), 382–389 (2006).
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J. Clin. Oncol. 26(14), 2264–2271 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Nademanee A, Ruel N et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol. Blood Marrow Transplant. 12(12), 1326–1334 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg Jd, Chou Jf, Horwitz S et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk. Lymphoma 53(6), 1124–1129 (2012).
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 22(11), 2172–2176 (2004).
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 103(2), 428–434 (2004).
   PubMed Web of Science ®Google Scholar
• Wulf Gg, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 36(3), 271–273 (2005).
   PubMed Web of Science ®Google Scholar
• Shustov Ar, Gooley Ta, Sandmaier Bm et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br. J. Haematol. 150(2), 170–178 (2010).
   PubMed Web of Science ®Google Scholar
• Zain J, Palmer JM, Delioukina M et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk. Lymphoma 52(8), 1463–1473 (2011).
   PubMed Web of Science ®Google Scholar
• Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 47(1), 65–72 (2012).
   PubMed Web of Science ®Google Scholar
• Dodero A, Spina F, Narni F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3), 520–526 (2012).
   PubMed Web of Science ®Google Scholar
• Corradini PV, Rambaldi A, Miceli R, Patriarca F, Gallamini A. Intensified chemo-immunotherapy including up-front autologous or allogeneic stem cell transplantation (SCT) for young patients with newly diagnosed peripheral T-cell lymphomas: final results of a Phase II multicenter prospective clinical trial. Blood Abstract(120), 1984 (2012).
   Google Scholar
• Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J. Clin. Oncol. 19(17), 3766–3770 (2001).
   Google Scholar
• Barrett Aj, Savani Bn. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20(10), 1661–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 37(4), 425–431 (2006).
   PubMed Web of Science ®Google Scholar
• Izutsu K, Kanda Y, Ohno H et al. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood 103(5), 1955–1960 (2004).
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Finke J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J. Clin. Oncol. 27(24), 3951–3958 (2009).
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Fujii N et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. Leuk. Lymphoma 52(7), 1255–1261 (2011).
   PubMed Web of Science ®Google Scholar
• Lin Hn, Liu Cy, Pai Jt et al. How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models? Blood Cancer J. 2, e93 (2012).
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett Nl, Leonard Jp et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812–1821 (2010).
   PubMed Web of Science ®Google Scholar
• Casulo CZ, Moskowitz C, Horwitz S. Negative interim FDG-PET scan is predictive of superior outcome in T cell lymphoma. Blood 114(22), 1956 (2009).
   Google Scholar
• Kim MK, Kim S, Lee SS et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann. Hematol. 86(6), 435–442 (2007).
   PubMed Web of Science ®Google Scholar
• O'connor Oa, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29(9), 1182–1189 (2011).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince Hm et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6), 631–636 (2012).
   PubMed Web of Science ®Google Scholar
• Damaj G, Bouabdallah K. Preliminary results from an open-label, multicentric, Phase II study of bendamustine in relapsed or refractory T-cell lymphoma from the French GOELAMS group: the BENTLY trial. Ann. Oncol. 22(4), 125 (2011).
   Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28(9), 1591–1598 (2010).
   PubMed Web of Science ®Google Scholar
• Qi W, Spier C, Liu X et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk. Res. 37(4), 434–439 (2013).
   PubMed Web of Science ®Google Scholar
• Dreyling M, Thieblemont C, Gallamini A et al. ESMO consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncol. 24(4), 857–877 (2013).
   PubMed Web of Science ®Google Scholar